RedHill Biopharma says USPTO has issued it with two new patents for opaganib for Ebola Virus and RHB-104 for Crohn'sProactive Investors • 08/23/21
RedHill Biopharma Announces Two New U.S. Patents Covering Opaganib for Ebola Virus and RHB-104 for Crohn'sPRNewsWire • 08/23/21
RedHill Biopharma to Host Second Quarter 2021 Financial Results and Operational Highlights Webcast on August 26, 2021PRNewsWire • 08/19/21
RedHill Biopharma Announces Settlement of Movantik® Patent Litigation with ApotexPRNewsWire • 07/22/21
RedHill Biopharma Significantly Extends Unrestricted Commercial Coverage for Talicia® with OptumRxPRNewsWire • 07/20/21
RedHill Biopharma completes treatment and follow-up in the 475-patient global Phase 2/3 COVID-19 study with opaganibProactive Investors • 07/19/21
RedHill Biopharma Announces Last Patient Out for Phase 2/3 COVID-19 Study of Oral OpaganibPRNewsWire • 07/19/21
RedHill Biopharma's Movantik® Added as Unrestricted Preferred Brand To A Major National Commercial Formulary Serving over 30 Million AmericansPRNewsWire • 07/13/21
RedHill Biopharma reports preliminary results from new preclinical study showing potent inhibition of COVID-19 variants by opaganibProactive Investors • 06/28/21
RedHill Biopharma presents positive Phase 2 data for oral opaganib in hospitalized patients with COVID-19 at World Microbe ForumProactive Investors • 06/22/21
RedHill Biopharma Announces Presentation of Positive Oral Opaganib Phase 2 Data in COVID-19PRNewsWire • 06/21/21
RedHill completes enrollment in the global Phase 2/3 severe COVID-19 study with oral opaganibProactive Investors • 06/08/21
RedHill Biopharma Completes Enrollment of Oral Opaganib Phase 2/3 COVID-19 StudyPRNewsWire • 06/07/21
RedHill Biopharma highlights strong end to first-quarter and almost 100% enrollment in opaganib's Phase 2/3 study for COVID-19Proactive Investors • 06/01/21
RedHill Biopharma Ltd.'s (RDHL) CEO Dror Ben-Asher on Q1 2021 Results - Earnings Call TranscriptSeeking Alpha • 05/27/21
Strength Seen in Redhill Biopharma Ltd. (RDHL): Can Its 5.4% Jump Turn into More Strength?Zacks Investment Research • 05/27/21